Rhodanine as a privileged scaffold in drug discovery

Current Medicinal Chemistry

Volumn 16, Issue 13, 2009, Pages 1596-1629

  Tomasic T ^a   Mašič, Lucija Petrlin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Privileged scaffold; Pseudothiohydantoin; Rhodanine; Thiazolidine 2,4 dione

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 2 IMINOTHIAZOLIDIN 4 ONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSE REDUCTASE INHIBITOR; ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTHRAX LETHAL FACTOR INHIBITOR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BENZYLIDENE RHODANINE; BETA LACTAMASE INHIBITOR; BOTULINUM TOXIN; CIGLITAZONE; CYCLOOXYGENASE 2 INHIBITOR; D 157070; DARBUFELONE; EPALRESTAT; FUNGAL PROTEIN MANNOSYL TRANSFERASE 1 INHIBITOR; INDOL 2,3 DIONE; NONSTRUCTURAL PROTEIN 3 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHOSPHODIESTERASE IV; RHODANINE; RHODANINE DERIVATIVE; RNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZENARESTAT; ANTIINFECTIVE AGENT; ENZYME INHIBITOR;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BINDING AFFINITY; CELL PROLIFERATION; CELL WALL; COMPETITIVE INHIBITION; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FUNGAL CELL; IC 50; MELANOGENESIS; MINIMUM INHIBITORY CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSLATION INITIATION; CHEMISTRY; DRUG DEVELOPMENT; DRUG SCREENING;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; RHODANINE;

EID: 67650261319     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788186200     Document Type: Review

References (184)

1. Brown, F.C. 4-Thiazolidinones. Chem. Rev., 1961, 61, 463-521.
2. Singh, S.P.; Parmar, S.S.; Raman, K.; Stenberg, V.I. Chemistry and biological activity of thiazolidinones. Chem. Rev., 1981, 81, 175-203.
3. Lesyk, R.B.; Zimenkovsky, B.S. 4-Thiazolidones: Centenarian history, current status and perspectives for modern organic and medicinal chemistry. Curr. Org. Chem., 2004, 8, 1547-77.
4. Silver, L.L. Novel inhibitors of bacterial cell wall synthesis. Curr. Opin. Microbiol., 2003, 6, 431-8.
5. Pardasani, R.T.; Pardasani, P.; Sherry, D.; Chaturvedi, V. Synthetic and antibacterial studies of rhodanine derivatives with indol-2,3-diones. Indian J. Chem., Sect B, 2001, 40, 1275-8.
6. Grant, E.B.; Guiadeen, D.; Baum, E.Z.; Foleno, B.D.; Jin, H.; Montenegro, D.A.; Nelson, E.A.; Bush, K.; Hlasta, D.J. The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2179-82.
7. Gandhe, S.; Gautam, M.D. Synthesis and microbial activity of 5-(2-methyl-4-N-cyanoethyl-N-benzenesulphonyl aminobenzylidene) rhodanine and its metal complexes. Asian J. Chem., 2004, 16, 261-4.
8. Scherman, M.S.; Winans, K.A.; Stern, R.J.; Jones, V.; Bertozzi, C.R.; McNeil, M.R. Drug targeting Mycobacterium tuberculosis cell wall synthesis: Development of a microtiter plate-based screen for UDP-galactopyranose mutase and identification of an inhibitor from a uridine-based library. Antimicrob. Agents Chemother., 2003, 47, 378-82.
9. Soltero-Higgin, M.; Carlson, E.E.; Phillips, J.H.; Kiessling, L.L. Identification of inhibitors for UDP-galactopyranose mutase. J. Am. Chem. Soc., 2004, 126, 10532-3.
10. Carlson, E.E.; May, J.F.; Kiessling, L.L. Chemical probes of UDP-galactopyranose mutase. Chem. Biol., 2006, 13, 825-37.
11. Andres, C.J.; Bronson, J.J.; D'Andrea, S.V.; Deshpande, M.S.; Falk, P.J.; Grant-Young, K.A.; Harte, W.E.; Ho, H.-T.; Misco, P.F.; Robertson, J.G.; Stock, D.; Sun, Y.; Walsh, A.W. 4-Thiazolidinones: Novel inhibitors of the bacterial enzyme MurB. Bioorg. Med. Chem. Lett., 2000, 10, 715-7.
12. Sim, M.M.; Ng, S.B.; Buss, A.D.; Crasta, S.C.; Goh, K.L.; Lee, S.K. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase. Bioorg. Med. Chem. Lett., 2002, 12, 697-9.
13. Helm, J.S.; Hu, Y.; Chen, L.; Gross, B.; Walker, S. Identification of active-site inhibitors of MurG using a generalizable, high-throughput glycosyltransferase screen. J. Am. Chem. Soc., 2003, 125, 11168-9.
14. Hu, Y.; Helm, J.S.; Chen, L.; Ginsberg, C.; Gross, B.; Kraybill, B.; Tiyanont, K.; Fang, X.; Wu, T.; Walker, S. Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening. Chem. Biol., 2004, 11, 703-11.
15. van Heijenoort, J. Recent advances in the formation of the bacterial peptidoglycan monomer unit. Nat. Prod. Rep., 2001, 18, 503-19.
16. Zervosen, A.; Lu, W.-P.; Chen, Z.; White, R.E.; Demuth Jr., T.P.; Frere, J.-M. Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones. Antimicrob. Agents Chemother., 2004, 48, 961-9.
17. Gualtieri, M.; Bastide, L.; Villain-Guillot, P.; Michaux-Charachon, S.; Latouche, J.; Leonetti, J.-P. In vitro activity of a new antibacterial rhodanine derivative against Staphylococcus epidermidis biofilms. J. Antimicrob. Chemother., 2006, 58, 778-83.
18. Villain-Guillot, P.; Gualtieri, M.; Bastide, L.; Roquet, F.; Martinez, J.; Amblard, M.; Pugniere, M.; Leonetti, J.-P. Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. J. Med. Chem., 2007, 50, 4195-204.
19. André, E.; Bastide, L.; Michaux-Charachon, S.; Gouby, A.; Villain-Guillot, P.; Latouche, J.; Bouchet, A.; Gualtieri, M.; Leonetti, J.-P. Novel synthetic molecules targeting the bacterial RNA polymerase assembly. J. Antimicrob. Chemother., 2006, 57, 245-51.
20. Villain-Guillot, P.; Gualtieri, M.; Bastide, L.; Leonetti, J.-P. In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm. Antimicrob. Agents Chemother., 2007, 51, 3117-21.
21. Mitchinson, D.A. A new antituberculosis drug that selectively kills nonmultiplying Mycobacterium tuberculosis. Cell Host Microbe, 2008, 3, 122-4.
22. Bryk, R.; Gold, B.; Venugopal, A.; Singh, J.; Samy, R.; Pupek, K.; Cao, H.; Popescu, C.; Gurney, M.; Hotha, S.; Cherian, J.; Rhee, K.; Ly, L.; Converse, P.J.; Ehrt, S.; Vandal, O.; Jiang, X.; Schneider, J.; Lin, G.; Nathan, C. Selective killing of nonreplicating mycobacteria. Cell Host Microbe, 2008, 3, 137-45.
23. Singh, J.; Nathan, C.F.; Bryk, R.; Samy, R.; Pupek, K.; Gurney, M. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis. WO 2008005651 A2 2008.
24. Ma, Y.; Stern, R.J.; Scherman, M.S.; Vissa, V.D.; Yan, W.; Jones, V.C.; Zhang, F.; Franzblau, S.G.; Lewis, W.H.; McNeil, M.R. Drug targeting Mycobacterium tuberculosis cell wall synthesis: Genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob. Agents Chemother., 2001, 45, 1407-16.
25. Forino, M.; Johnson, S.; Wong, T.Y.; Rozanov, D.V.; Savinov, A.Y.; Li, W.; Fattorusso, R.; Becattini, B.; Orry, A.J.; Jung, D.; Abagyan, R.A.; Smith, J.W.; Alibek, K.; Liddington, R.C.; Strongin, A.Y.; Pellecchia, M. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 9499-504.
26. Johnson, S.L.; Jung, D.; Forino, M.; Chen, Y.; Satterthwait, A.; Rozanov, D.V.; Strongin, A.Y.; Pellecchia, M. Anthrax lethal factor protease inhibitors: Synthesis, SAR, and structure-based 3D QSAR studies. J. Med. Chem., 2006, 49, 27-30.
27. Johnson, S.L.; Chen, L.-H., Harbach, R.; Sabet, M.; Savinov, A.; Cotton, N.J.H.; Strongin, A.; Guiney, D.; Pellecchia, M. Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Chem. Biol. Drug Des., 2008, 71, 131-9.
28. Heerding, D.A.; Christmann, L.T.; Clark, T.J.; Holmes, D.J.; Rittenhouse, S.F.; Takata, D.T.; Venslavsky, J.W. New benzylidenethiazolidinediones as antibacterial agents. Bioorg. Med. Chem. Lett., 2003, 13, 3771-3.
29. Tunçbilek, M.; Altanlar, N. Synthesis and antimicrobial evaluation of some 3-(substituted phenacyl)-5-[4-(4H-4-oxo-1-benzopyran-2-yl)- benzylidene]-2,4-thiazolidinediones. FARMACO, 1999, 54, 475-8.
30. Kocabalkanli, A.; Ates, Ö.; Ötük, G. Synthesis of Mannich bases of some 2,5-disubstituted 4-thiazolidinones and evaluation of their antimicrobial activities. Arch. Pharm. Pharm. Med. Chem., 2001, 334, 35-9.
31. Orchard, M.G.; Neuss, J.C.; Galley, C.M.S.; Carr, A.; Porter, D.W.; Smith, P.; Scopes, D.I.C.; Haydon, D.; Vousden, K.; Stubberfield, C.R.; Young, K.; Page, M. Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1). Bioorg. Med. Chem. Lett., 2004, 14, 3975-8.
32. Sortino, M.; Delgado, P.; Juárez, S.; Quiroga, J.; Abonía, R.; Insuasty, B.; Nogueras, M.; Rodero, L.; Garibotto, F.M.; Enriz, R.D.; Zacchino, S.A. Synthesis and antifungal activity of (Z)-5-arylidenerhodanines. Bioorg. Med. Chem., 2007, 15, 484-94.
33. Bradsher, C.K.; Brown, F.C.; Grantham, R.J. Synthesis and fungistatic activity of some 5-(1-methyl-2-thioalkylethylidene)-rhodanines. J. Am. Chem. Soc., 1954, 76, 114-5.
34. Inamori, Y.; Okamoto, Y.; Takegawa, Y.; Tsujibo, H.; Sakagami, Y.; Kumeda, Y.; Shibata, M.; Numata, A. Insecticidal and antifungal activities of aminorhodanine derivatives. Biosci. Biotechnol. Biochem., 1998, 62, 1025-7.
35. Yadav, L.D.S.; Tripathi, R.K.; Dwivedi, R.; Singh, H. Chemoselective heterocyclizations of (4-oxo-2-thioxothiazolidin-5-yl)-N-aryldithiocarbamates to antifungal 1,3-dithiolo-, 1,3-oxathiolo, and thiazolothiazoles. J. Agric. Food Chem., 1992, 40, 1700-2.
36. Habib, N.S.; Rida, S.M.; Badawey, E.A.M.; Fahmy, H.T.Y.; Ghozlan, H.A. Synthesis and antimicrobial activity of rhodanine derivatives. Eur. J. Med. Chem., 1997, 32, 759-62.
37. Siddiqui, I.R.; Singh, P.K., Singh, J.; Singh, J. Facile synthesis and fungicidal activity of novel 4,4'-bis[2"-(5"'-substituted rhodanin-3"'-yl) thiazol-4"yl]bibenzyls. Indian J. Chem., Sect B, 2005, 44, 2102-6.
38. Yan, S.; Appleby, T.; Larson, G.; Wu, J.Z.; Hamatake, R.; Hong, Z.; Yao, N. Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5888-91.
39. Sudo, K.; Matsumoto, Y.; Matsushima, M.; Fujiwara, M.; Konno, K.; Shimotohno, K.; Shigeta, S.; Yokota, T. Novel hepatitis C virus protease inhibitors: Thiazolidine derivatives. Biochem. Biophys. Res. Commun., 1997, 238, 643-7.
40. Sing, W.T.; Lee, C.L.; Yeo, S.L.; Lim, S.P.; Sim, M.M. Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorg. Med. Chem. Lett., 2001, 11, 91-4.
41. Powers, J.P.; Piper, D.E.; Li, Y.; Mayorga, V.; Anzola, J.; Chen, J.M.; Jaen, J.C.; Lee, G.; Liu, J.; Peterson, M.G.; Tonn, G.R.; Ye, Q.; Walker, N.P.C.; Wang, Z. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem., 2006, 49, 1034-46.
42. Yan, S.; Larson, G.; Wu, J.Z.; Appleby, T.; Ding, Y.; Hamatake, R.; Hong, Z.; Yao, N. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure. Bioorg. Med. Chem. Lett., 2007, 17, 63-7.
43. Yan, S.; Appleby, T.; Larson, G.; Wu, J.Z.; Hamatake, R.K.; Hong, Z.; Yao, N. Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: Convergence of structure-based drug design and X-ray crystallographic study. Bioorg. Med. Chem. Lett., 2007, 17, 1991-5.
44. Ding, Y.; Smith, K.L.; Varaprasad, C.V.N.S.; Chang, E.; Alexander, J.; Yao, N. Synthesis of thiazolone-based sulfonamides as inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett., 2007, 17, 841-5.
45. Dayam, R.; Sanchez, T.; Clement, O.; Shoemaker, R.; Sei, S.; Neamati, N. β-Diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J. Med. Chem., 2005, 48, 111-20.
46. Kumar, G.; Parasuraman, P.; Sharma, S.K.; Banerjee, T.; Karmodiya, K.; Surolia, N.; Surolia, A. Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. J. Med. Chem., 2007, 50, 2665-75.
47. Kawakami, M.; Koya, K.; Ukai, T.; Tatsuta, N.; Ikegawa, A.; Ogawa, K.; Shishido, T.; Chen, L.B. Synthesis and evaluation of novel rhodacyanine dyes that exhibit antitumor activity. J. Med. Chem., 1997, 40, 3151-60.
48. Kawakami, M.; Koya, K.; Ukai, T.; Tatsuta, N.; Ikegawa, A.; Ogawa, K.; Shishido, T.; Chen, L.B. Structure-activity of novel rhodacyanine dyes as antitumor agents. J. Med. Chem., 1998, 41, 130-42.
49. Takasu, K.; Inoue, H.; Kim, H.-S.; Suzuki, M.; Shishido, T.; Wataya, Y.; Ihara, M. Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity. J. Med. Chem., 2002, 45, 995-8.
50. Takasu, K.; Terauchi, H.; Inoue, H.; Kim, H.-S.; Wataya, Y.; Ihara, M. Parallel synthesis of antimalarial rhodacyanine dyes by the combination of three components in one pot. J. Comb. Chem., 2003, 5, 211-4.
51. Takasu, K.; Pudhom, K.; Kaiser, M.; Brun, R.; Ihara, M. Synthesis and antimalarial efficacy of aza-fused rhodacyanines in vitro and in the P. berghei mouse model. J. Med. Chem., 2006, 49, 4795-8.
52. Sudhakar, A.; Ramachandran, A.; Ghosh, S.; Hasnain, S.E.; Kaufman, R.J.; Ramaiah, K.V.A. Phosphorylation of serine 51 in initiation factor 2α (eIF2α) promotes complex formation between eIF2..(P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B.http://pubs.acs.org/doi/abs/10.1021/ bi0008682?prevSearch=%5Bauthor%3A+sudhakar%5D&searchHistoryKey=- bi0008682AF2 Biochemistry, 2000, 39, 12929-38.
53. Chen, H.; Fan, Y.-H.; Natarajan, A.; Guo, Y.; Iyasere, J.; Harbinski, F.; Luus, L.; Christ, W.; Aktas, H.; Halperin, J.A. Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg. Med. Chem. Lett., 2004, 14, 5401-5.
54. L. Nat. Cell Biol., 2001, 3, 173-82.
55. Lugovskoy, A.A.; Degterev, A.I.; Fahmy, A.F.; Zhou, P.; Gross, J.D.; Yuan, J.; Wagner, G. A novel approach for characterizing protein ligand complexes: Molecular basis for specificity of small-molecule Bcl-2 inhibitors. J. Am. Chem. Soc., 2002, 124, 1234-40
56. Bessette, D.C.; Qui, D.; Pallen, C.J. PRL PTPs: Mediators and markers of cancer progression. Cancer Metastasis Rev., 2008, 27, 231-52.
57. Ahn, J.H.; Kim, S.J.; Park, W.S.; Cho, S.Y.; Ha, J.D.; Kim, S.S.; Kang, S.K.; Jeong, D.G.; Jung, S.-K.; Lee, S.-H.; Kim, H.M.; Park, S.K.; Lee, K.H.; Lee, C.W.; Ryu, S.E.; Choi, J.-K. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 2996-9.
58. Park, H.; Jung, S.-K.; Jeong, D.G.; Ryu, S.E.; Kim, S.J. Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening. Bioorg. Med. Chem. Lett., 2008, 18, 2250-5.
59. Cutshall, N.S.; O'Day, C.; Prezhdo, M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg. Med. Chem. Lett., 2005, 15, 3374-9.
60. French, K.J.; Schrecengost, R.S.; Lee, B.D.; Zhuang, Y.; Smith, S.N.; Eberly, J.L.; Yun, J.K.; Smith, C.D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63, 5962-9.
61. Huwiler, A.; Zangemeister-Wittke, U. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit. Rev. Oncol. Hemat., 2007, 63, 150-9.
62. Kubota, T.; Koshizuka, K.; Williamson, E.A.; Asou, H.; Said, J.W.; Holden, S.; Miyoshi, I.; Koeffler, H.P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 1998, 58, 3344-52.
63. Panigrahy, D.; Singer, S.; Shen, L.Q.; Butterfield, C.E.; Freedman, D.A.; Chen, E.J.; Moses, M.A.; Kilroy, S.; Duensing, S.; Fletcher, C.; Fletcher, J.A.; Hlatky, L.; Hahnfeldt, P.; Folkman, J.; Kaipainen, A. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest., 2002, 110, 923-32.
64. Sarraf, P.; Mueller, E.; Jones, D.; King, F.J.; DeAngelo, D.J.; Partridge, J.B.; Holden, S.A.; Chen, L.B.; Singer, S.; Fletcher, C.; Spiegelman, B.M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat.Med., 1998, 4, 1046-52.
65. Huang, J.-W.; Shiau, C.-W.; Yang, Y.-T.; Kulp, S.K.; Chen, K.-F.; Brueggemeier, R.W.; Shapiro, C.L.; Chen, C.-S. Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol. Pharmacol., 2005, 67, 1342-8.
66. Huang, J.-W.; Shiau, C.-W.; Yang, J.; Wang, D.-S.; Chiu, H.-C.; Chen, C.-Y.; Chen, C.-S. Development of small-molecule cyclin D1-ablative agents. J. Med. Chem., 2006, 49, 4684-9.
67. Palakurthi, S.S.; Aktas, H.; Grubissich, L.M.; Mortensen, R.M.; Halperin, J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res., 2001, 61, 6213-8.
68. Fan, Y.-H.; Chen, H.; Natarajan, A.; Guo, Y.; Harbinski, F.; Iyasere, J.; Christ, W.; Aktas, H.; Halperin, J.A. Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg. Med. Chem. Lett., 2004, 14, 2547-50.
69. Yang, J.; Wei, S.; Wang, D.-S.; Wang, Y.-C.; Kulp, S.K.; Chen, C.-S. Pharmacological exploitation of the peroxisome proliferator-activated receptor γ agonist ciglitazone to develop a novel class of androgen receptor-ablative agents. J. Med. Chem., 2008, 51, 2100-7.
70. +-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Arch. Biochem. Biophys., 2002, 405, 247-51.
71. Teraishi, F.; Wu, S.; Sasaki, J.; Zhang, L.; Davis, J.J.; Guo, W.; Dong, F.; Fang, B. JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell. Mol. Life Sci., 2005, 62, 2382-9.
72. Moretti, R.M.; Marelli, M.M.; Motta, M.; Limonta, P. Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. Int. J. Cancer, 2001, 92, 733-7.
73. Sussman, F.; de Lera, A.R. Ligand recognition by RAR and RXR receptors: binding and selectivity. J. Med. Chem., 2005, 48, 6212-9.
74. Dawson, M.I.; Xia, Z.; Liu, G.; Fontana, J.A.; Farhana, L.; Patel, B.B.; Arumugarajah, S.; Bhuiyan, M.; Zhang, X.-K.; Han, Y.-H.; Stallcup, W.B.; Fukushi, J.; Mustelin, T.; Tautz, L.; Su, Y.; Harris, D.L.; Waleh, N.; Hobbs, P.D.; Jong, L.; Chao, W.; Schiff, L.J.; Sani, B.P. An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity. J. Med. Chem., 2007, 50, 2622-39.
75. Chen, S.; Chen, L.; Le, N.T.; Zhao, C.; Sidduri, A.; Lou, J.P.; Michoud, C.; Portland, L.; Jackson, N.; Liu, J.J.; Konzelmann, F.; Chi, F.; Tovar, C.; Xiang, Q.; Chen, Y.; Wen, Y.; Vassilev, L.T. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2134-8.
76. Lesyk, R.; Zimenkovsky, B.; Atamanyuk, D.; Jensen, F.; Kieć-Kononowicz, K.; Gzella, A. Anticancer thiopyrano[2,3-d][1,3thiazol-2-ones with norbornane moiety. Synthesis, cytotoxicity, physico-chemical properties, and computational studies. Bioorg. Med. Chem., 2006, 14, 5230-40
77. Hossain, S.U.; Bhattacharya, S. Synthesis of O-prenylated and O-geranylated derivatives of 5-benzylidene2,4-thiazolidinediones and evaluation of their free radical scavenging activity as well as effect on some phase II antioxidant/detoxifying enzymes. Bioorg. Med. Chem. Lett., 2007, 17, 1149-54.
78. 2. J. Med. Chem., 2000, 43, 1041-4.
79. Unangst, P.C.; Connor, D.T.; Cetenko, W.A.; Sorenson, R.J.; Kostlan, C.R.; Sircar, J.C.; Wright, C.D.; Shrier, D.J.; Dyer, R.D. Synthesis and biological evaluation of 5- 3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl] methylene]oxazoles, -thiazoles, and -imidazoles: Novel dual 5-lipoxygenase and cyclooxygenase inhibitors with anti-inflammatory activity. J. Med. Chem., 1994, 37, 322-8.
80. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem., 2003, 38, 645-59.
81. Song, Y.; Connor, D.T.; Doubleday, R.; Sorenson, R.J.; Sercel, A.D.; Unangst, P.C.; Roth, B.D.; Gilbertsen, R.B.; Chan, K.; Schrier, D.J.; Guglietta, A.; Bornemeier, D.A.; Dyer, R.D. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J. Med. Chem., 1999, 42, 1151-60.
82. Nasr, M.N.A.; Said, S.A. Novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivatives as anti-inflammatory agents. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 551-9.
83. Ali, A.M.; Saber, G.E.; Mahfouz, N.M.; El-Gendy, M.A.; Radwan, A.A.; Hamid, M.A.-E. Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors. Arch. Pharm. Res., 2007, 30, 1186-204.
84. Panetta, J.A.; Shadle, J.K.; Phillips, M.L.; Benslay, D.N.; Ho, P.P. 4-Thiazolidinones, potent antioxidants, as antiinflammatory agents. Ann. N.Y. Acad. Sci., 1993, 696, 415-6.
85. Slattery, B.J.; Kjell, D.P.; Copp, J.D.; Ginah, F.O.; Hansen, M.M.; Stirm, S.C. The development of a manufacturable synthesis of LY213829. Org. Process Res. Dev., 2000, 4, 295-7.
86. Jeong, T.-S.; Kim, J.-R.; Kim, K.S.; Cho, K.-H.; Bae, K.-H.; Lee, W.S. Inhibitory effects of multi-substituted benzylidenethiazolidine-2,4-diones on LDL oxidation. Bioorg. Med. Chem., 2004, 12, 4017-23.
87. Silva, A.A.R.; Góes, A.J.S.; Lima, W.T.; Maia, M.B.S. Antiedematogenic activity of two thiazolidine derivatives: N- tryptophyl-5-(3,5-di-tert- butyl-4-hydroxybenzylidene) rhodanine (GS26) and N-tryptophyl-5-(3,5-di-tert-butyl-4- hydroxybenzylidene)-2,4-thiazolidinedione (GS28). Chem. Pharm. Bull., 2003, 51, 1351-5.
88. Irvine, M.W.; Patrick, G.L.; Kewney, J.; Hastings, S.F.; MacKenzie, S.J. Rhodanine derivatives as novel inhibitors of PDE4. Bioorg. Med. Chem. Lett., 2008, 18, 2032-7.
89. Camps, M.; Ruckle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Fran&on, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy,D.; Vitte, P.-A.; Hirsch, E.; Wymann, M.P.; Cirillo, R.; Schwarz, M.K.; Rommel, C. Blockade of PI3K.. suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nature Med., 2005, 11, 936-43.
90. Pomel, V.; Klicic, J.; Covini, D.; Church, D.D.; Shaw, J.P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C.; Gillieron, C.; Fran&on, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P.A.; Carboni, S.; Rommel, C.; Schwarz, M.K.; Rückle, T. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem., 2006, 49, 3857-71.
91. Carter, P.H.; Scherle, P.A.; Muckelbauer, J.A.; Voss, M.E.; Liu, R.-Q.; Thompson, L.A.; Tebben, A.J.; Solomon, K.A.; Lo, Y.C.; Li, Z.; Strzemienski, P.; Yang, G.; Falahatpisheh, N.; Xu, M.; Wu, Z.; Farrow, N.A.; Ramnarayan, K.; Wang, J.; Rideout, D.; Yalamoori, V.; Domaille, P.; Underwood, D.J.; Trzaskos, J.M.; Friedman, S.M.; Newton, R.C.; Decicco, C.P. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 11879-84
92. Gilbert, A.M.; Bursavich, M.G.; Lombardi, S.; Georgiadis, K.E.; Reifenberg, E.; Flannery, C.R.; Morris, E.A. 5-((1H-Pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5. Bioorg. Med. Chem. Lett., 2007, 17, 1189-92.
93. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82.
94. Missbach, M.; Jagher, B.; Sigg, I.; Nayeri, S.; Carlberg, C.; Wiesenberg, I. Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor α with potent antiarthritic activity. J. Biol. Chem., 1996, 271, 13515-22.
95. Wiesenberg, I.; Chiesi, M.; Missbach, M.; Spanka, C.; Pignat, W.; Carlberg, C. Specific activation of the nuclear receptors PPARγ and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608. Mol. Pharmacol., 1998, 53, 1131-8.
96. Pickhardt, M.; von Bergen, M.; Gazova, Z.; Hascher, A.; Biernat, J.; Mandelkow, E.-M.; Mandelkow, E. Screening for inhibitors of tau polymerization. Curr. Alzheimer Res., 2005, 2, 219-26.
97. Bulic, B.; Pickhardt, M.; Khlistunova, I.; Biernat, J.; Mandelkow, E.-M.; Mandelkow, E.; Waldmann, H. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed., 2007, 46, 9215-9.
98. Whitesitt, C.A.; Simon, R.L.; Reel, J.K.; Sigmund, S.K.; Phillips, M.L.; Shadle, J.K.; Heinz, L.J.; Koppel, G.A.; Hunden, D.C.; Lifer, S.L.; Berry, D.; Ray, J.; Little, S.P.; Liu, X.; Marshall, W.S.; Panetta, J.A. Synthesis and structure-activity relationships of benzophenones as inhibitors of cathepsin D. Bioorg. Med. Chem. Lett., 1996, 6, 2157-62.
99. Terashima, H.; Hama, K.; Yamamoto, R.; Tsuboshima, M.; Kikkawa, R.; Hatanaka, I.; Shigeta, Y. Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharmacol. Exp. Ther., 1984, 229, 226-30.
100. Kador, P.F.; Kinoshita, J.H.; Sharpless, N.E. Aldose reductase inhibitors: A potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem., 1985, 28, 841-9.
101. Maccari, R.; Ottana, R.; Curinga, C.; Vigorita, M.G.; Rakowitz, D.; Steindl, T.; Langer, T. Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. Bioorg. Med. Chem., 2005, 13, 2809-23.
102. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barloco, D. Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches. Med. Res. Rev., 1999, 1, 3-23.
103. Lee, Y.S.; Chen, Z.; Kador, P.F. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Bioorg. Med. Chem., 1998, 6, 1811-9.
104. Fresneau, P.; Cussac, M.; Morand, J.-M.; Szymonski, B.; Tranqui, D.; Leclerc, G. Synthesis, activity, and molecular modeling of new 2,4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors. J. Med. Chem., 1998, 41, 4706-15.
105. Murata, M.; Fujitani, B.; Mizuta, H. Synthesis and aldose reductase inhibitory activity of a new series of 5- 2-(Ω-carboxyalkoxy) aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives. Eur. J. Med. Chem., 1999, 34, 1061-70.
106. Bruno, G.; Costantino, L.; Curinga, C.; Maccari, R.; Monforte, F.; Nicolò, F.; Ottanà, R.; Vigorita, M.G. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem., 2002, 10, 1077-84.
107. Rakowitz, D.; Maccari, R.; Ottanà, R.; Vigorita, M.G. In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones. Bioorg. Med. Chem., 2006, 14, 567-74.
108. Maccari, R.; Ottanà, R.; Ciurleo, R.; Vigorita, M.G.; Rakowitz, D.; Steindl, T.; Langer, T. Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem. Lett., 2007, 17, 3886-93.
109. Maccari, R.; Ottanà, R.; Ciurleo, R.; Rakowitz, D.; Matuszczak, B.; Laggner, C.; Langer, T. Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives. Bioorg. Med. Chem., 2008, 16, 5840-52.
110. Sambasivarao, S.V.; Soni, L.K.; Gupta, A.K.; Hanumantharao, P.; Kaskhedikar, S.G. Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 512-20.
111. Bozdaǧ-Dündar, O.; Daş-Evcimen, N.; Ceylan-Ünlüsoy, M.; Ertan, R.; Sarikaya, M. Some new thiazolyl thiazolidinedione derivatives as aldose reductase inhibitors. Med. Chem. Res., 2007, 16, 39-47.
112. Bozdaǧ-Dündar, O.; Evranos, B.; Daǧ-Evcimen, N.; Sarikaya, M.; Ertan, R. Synthesis and aldose reductase inhibitory activity of some new chromonyl-2,4-thiazolidinediones. Eur. J. Med. Chem., 2008, 43, 2412-7.
113. Bozdaǧ-Dündar, O.; Verspohl, E.J.; Daǧ-Evcimen, N.; Kaup, R.M.; Bauer, K.; Sarikaya, M.; Evranos, B.; Ertan, R. Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones. Bioorg. Med. Chem., 2008, 16, 6747-51.
114. Sohda, T.; Mizuno, K.; Imamiya, E.; Tawada, H.; Meguro, K.; Kawamatsu Yamamoto, Y. Studies on antidiabetic agents. III. 5-Arylthiazolidine-2,4-diones as potent aldose reductase inhibitors. Chem. Pharm. Bull., 1982, 30, 3601-16.
115. Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem., 1989, 32, 421-8.
116. Sohda, T.; Momose, Y.; Meguro, K.; Kawamatsu, Y.; Sugiyama, Y.; Ikeda, H. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch./Drug Res., 1990, 40, 37-42.
117. Cantello, B.C.; Cawthorne, M.A.; Cottam, G.P.; Duff, P.T.; Haigh, D.; Hindley, R.M.; Lister, C.A.; Snith, S.A.; Thurlby, P.L. Ω-(Heterocyclylamino) alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 1994, 37, 3977-85.
118. Berger, J.P.; Akiyama, T.E.; Meinke, P.T. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol. Sci., 2005, 26, 244-51.
119. Fujiwara, T.; Horikoshi, H. Troglitazone and related compounds: Therapeutic potential beyond diabetes. Life Sci., 2000, 67, 2405-16.
120. Abrahamson, M.J. Clinical use of thiazolidinediones: Recommendations. Am. J. Med., 2003, 115, 116-20.
121. Quinn, C.E.; Hamilton, P.K.; Lockhart, C.J.; McVeigh, G.E. Thiazolidinediones: Effects on insulin resistance and the cardiovascular system. Br. J. Pharmacol., 2008, 153, 636-45.
122. Hulin, B.; Clark, D.A.; Goldstein, S.W.; McDermott, R.E.; Dambek, P.J.; Kappeler, W.H.; Lamphere, C.H.; Lewis, D.M.; Rizzi, J.P. Novel thiazolidine-2,4-diones as potent euglycemic agents. J. Med. Chem., 1992, 35, 1853-64.
123. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. J. Med. Chem., 1992, 35, 2617-26.
124. Lohray, B.B.; Bhushan, V.; Rao, P.B.; Madhavan, G.R.; Murali, N.; Rao, K.N., Reddy, K.A.; Rajesh, B.M.; Reddy, P.G.; Chakrabarti, R.; R1ajagopalan, R. Novel indole containing thiazolidinedione derivatives as potent euglycemic and hypolipidaemic agents. Bioorg. Med. Chem. Lett., 1997, 7, 785-8.
125. Reddy, K.A.; Lohray, B.B.; Bhushan, V.; Bajji, A.C.; Reddy, K.V.; Reddy, P.R.; Krishna, T.H.; Rao, I.N.; Jajoo, H.K.; Rao, N.V.S.M.; Chakrabarti, R.; Dileepkumar, T.; Rajagopalan, R. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones. J. Med. Chem., 1999, 42, 1927-40.
126. Bozdaǧ, O.; Verspohl, E.J.; Ertan, R. Synthesis and hypoglycemic activity of some new flavone derivatives. 2nd communication: 4'-flavonyl-2,4-thiazolidinediones. Arzneim.-Forsch./Drug Res., 2000, 50, 539-43.
127. Bozdaǧ, O.; Verspohl, E.J.; Ertan, R. Synthesis and hypoglycemic activity of some new flavone derivatives. 3rd communication: 3'-flavonyl-2,4-thiazolidinediones. Arzneim.-Forsch./Drug Res., 2000, 50, 626-30.
128. Bozdaǧ-Dündar, O.; Verspohl, E.J.; Waheed, A.; Ertan, R. Synthesis and antidiabetic activity of some new furochromonyl-2,4-thiazolidinediones. Arzneim.-Forsch./Drug Res., 2003, 53, 831-6.
129. Bozdaǧ-Dündar, O.; Ceylan-Ünlüsoy, M.; Verspohl, E.J.; Ertan, R. Synthesis and antidiabetic activity of novel 2,4-thiazolidinedione derivatives containing a thiazole ring. Arzneim.-Forsch./Drug Res., 2006, 56, 621-5.
130. Yanagisawa, H.; Takamura, M.; Yamada, E.; Fujita, S.; Fujiwara, T.; Yachi, M.; Isobe, A.; Hagisawa, Y. Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: Synthesis and structure-activity relationship. Bioorg. Med. Chem. Lett., 2000, 10, 373-5.
131. Momose, Y.; Maekawa, T.; Yamano, T.; Kawada, M.; Odaka, H.; Ikeda, H.; Sohda, T. Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. J. Med. Chem., 2002, 45, 1518-34.
132. Madhavan, G.R.; Chakrabarti, R.; Kumar, S.K.B.; Misra, P.; Mamidi, R.N.V.S.; Balraju, V.; Kasiram, K.; Babu, R.K.; Suresh, J.; Lohray, B.B.; Lohray, V.B., Iqbal, I.; Rajagopalan, R. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents. Eur. J. Med. Chem., 2001, 36, 627-37.
133. Madhavan, G.R.; Chakrabarti, R.; Vikramadithyan, R.K.; Mamidi, R.N.V.S.; Balraju, V.; Rajesh, B.M.; Misra, P.; Kumar, S.K.B.; Lohray, B.B.; Lohray, V.B.; Rajagopalan, R. Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives. Bioorg. Med. Chem., 2002, 10, 2671-80.
134. Koyama, H.; Boueres, J.K.; Han, W.; Metzger, E.J.; Bergman, J.P.; Gratale, D.F.; Miller, D.J.; Tolman, R.L.; MacNaul, K.L.; Berger, J.P.; Doebber, T.W.; Leung, K.; Moller, D.E.; Heck, J.V.; Sahoo, S.P. 5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists. Bioorg. Med. Chem. Lett., 2003, 13, 1801-4.
135. Neogi, P.; Lakner, F.J.; Medicherla, S.; Cheng, J.; Dey, D.; Gowri, M.; Nag, B.; Sharma, S.D.; Pickford, L.B.; Gross, C. Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents. Bioorg. Med. Chem., 2003, 11, 4059-67.
136. Kim, B.Y.; Ahn, J.B.; Lee, H.W.; Moon, K.S.; Sim, T.B.; Shin, J.S.; Ahn, S.K.; Hong, C.I. Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives. Chem. Pharm. Bull., 2003, 51, 276-85
137. Tunçbilek, M.; Bozdaǧ-Dündar, O.; Ayhan-Kilcigil, G.; Ceylan, M.; Waheed, A.; Verspohl, E.J.; Ertan, R. Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives - fifth communication: Flavonyl benzyl substituted 2,4-thiazolidinediones. Farmaco, 2003, 58, 79-83
138. Jeon, R.; Park, S. Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives. Arch. Pharm. Res., 2004, 27, 1099-105.
139. Bhat, B.A.; Ponnala, S.; Sahu, D.P.; Tiwari, P.; Tripathi, B.K.; Srivastava, A.K. Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives. Bioorg. Med. Chem., 2004, 12, 5857-64.
140. Kim, B.Y.; Ahn, J.B.; Lee, H.W.; Kang, S.K.; Lee, J.H.; Shin, J.S.; Ahn, S.K.; Hong, C.I.; Yoon, S.S. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur. J. Med. Chem., 2004, 39, 433-47.
141. Lee, H.W.; Kim, B.Y.; Ahn, J.B.; Kang, S.K.; Lee, J.H.; Shin, J.S.; Ahn, S.K.; Lee, S.J.; Yoon, S.S. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur. J. Med. Chem., 2005, 50, 862-74.
142. Mourão, R.H.; Silva, T.G.; Soares, A.L.M.; Vieira, E.S.; Santos, J.N.; Lima, M.C.A.; Lima, V.L.M.; Galdino, S.L.; Barbe, J.; Pitta, I.R. Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones. Eur. J. Med. Chem., 2005, 40, 1129-33.
143. Chittiboyina, A.G.; Venkatraman, M.S.; Mizuno, C.S.; Desai, P.V.; Patny, A.; Benson, S.C.; Ho, C.I.; Kurtz, T.W.; Pershadsingh, H.A.; Avery, M.A. Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists. J. Med. Chem., 2006, 49, 4072-84.
144. Jeon, R.; Kim, Y.-J.; Cheon, Y.; Ryu, J.-H. Synthesis and biological activity of (heterocycloamino)alkoxy benzyl-2,4-thiazolidinediones as PPARγ agonists. Arch. Pharm. Res., 2006, 29, 394-9.
145. Jung, S.H.; Park, S.Y.; Kim-Pak, Y.; Lee, H.K.; Park, K.S.; Shin, K.H.; Ohuchi, K.; Shin, H.-K.; Keum, S.R.; Lim, S.S. Synthesis and PPAR-γ ligand-binding activity of the new series of 2′-hydroxychalcone and thiazolidinedione derivatives. Chem. Pharm. Bull., 2006, 54, 368-71.
146. Gim, H.J.; Kang, B.; Jeon, R. Synthesis and biological activity of 5-{4-[2-(methyl-p-substituted phenylamino)ethoxy]benzyl}thiazolidine-2,4-diones. Arch. Pharm. Res., 2007, 30, 1055-61.
147. Chaudhry, J.; Ghosh, N.N.; Roy, K.; Chandra, R. Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life Sci., 2007, 80, 1135-42.
148. Li, Y.; Wang, Z.; Furukawa, N.; Escaron, P.; Weiszmann, J.; Lee, G.; Lindstrom, M.; Liu, J.; Liu, X.; Xu, H.; Plotnikova, O.; Prasad, V.; Walker, N.; Learned, R.M.; Chen, J.-L. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor γ binding properties. J. Biol. Chem., 2008, 283, 9168-76
149. Liu, Q.; Zhang, Y.; Lu, H.; Li, Q.; Zhou, C.; Wang, M. Rhodanine derivatives as novel peroxisome proliferator-activated receptor γ agonists. Acta Pharmacol. Sin., 2007, 12, 2033-9.
150. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-Substituted benzyl) thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg. Med. Chem. Lett., 1999, 9, 533-8.
151. Desai, R.C.; Han, W.; Metzger, E.J.; Bergman, J.P.; Gratale, D.F.; MacNaul, K.L.; Berger, J.P.; Doebber, T.W.; Leung, K.; Moller, D.E.; Heck, J.V.; Sahoo, S.P. 5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents. Bioorg. Med. Chem. Lett., 2003, 13, 2795-8.
152. Madhavan, G.R.; Chakrabarti, R.; Reddy, K.A.; Rajesh, B.M.; Balraju, V.; Rao, P.B.; Rajagopalan, R.; Iqbal, J. Dual PPAR-α and -γ activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential. Bioorg. Med. Chem., 2006, 14, 584-91.
153. Kumar, B.R.P.; Praveen, T.K.; Nanjan, M.J.; Karvekar, M.D.; Suresh, B. Serum glucose and triglyceride lowering activity of some novel glitazones against dexamethasone-induced hyperlipidemia and insulin resistance. Indian J. Pharmacol., 2007, 39, 299- 02.
154. Prabhakar, C.; Madhusudhan, G.; Sahadev, K.; Reddy, C.M.; Sarma, M.R.; Reddy, G.O.; Chakrabarti, R.; Rao, C.S.; Kumar, T.D.; Rajagopalan, R. Synthesis and biological activity of novel thiazolidinediones. Bioorg. Med. Chem. Lett., 1998, 8, 2725-30.
155. Maccari, R.; Paoli, P.; Ottanà, R.; Jacomelli, M.; Ciurleo, R.; Manao, G.; Steindl, T.; Langer, T.; Vigorita, M.G.; Camici, G. 5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorg. Med. Chem., 2007, 15, 5137-49.
156. Banerjee, R.K.; Gupta, R.C.; Tuli, D.; Rode, M.; Shuthar, B.; Umrani, D.; Pathak, P.; Choksi, T.; Chaudhary, A. Thiazolinones and oxazolinones and their use as PTP1B inhibitors. WO 2007032028 A1 2007.
157. Sheu, S.-Y.; Lin, C.-Y.; Wu, J.-D.; Chiang, H.-C. Inhibition of xanthine oxidase by benzothiazinone analogues. Anticancer Res., 1999, 19, 119-24.
158. Andreani, A.; Rambaldi, M.; Leoni, A.; Locatelli, A.; Bossa, R.; Chiericozzi, M.; Galatulas, I.; Salvatore, G. Synthesis and cardiotonic activity of imidazo[2,l-b]thiazoles bearing a lactam ring. Eur. J. Med. Chem., 1996, 31, 383-7.
159. Free, C.A.; Majchrowicz, E.; Hess, S.M. Mechanism of inhibition of histidine decarboxylase by rhodanines. Biochem. Pharmacol., 1971, 20, 1421-8.
160. Ge, X.; Wakim, B.; Sem, D.S. Chemical proteomics-based drug design: Target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins. J. Med. Chem., 2008, 51, 4571-80.
161. Sem, D.S.; Bertolaet, B.; Baker, B.; Chang, E.; Costache, A.D.; Coutts, S.; Dong, Q.; Hansen, M.; Hong, V.; Huang, X.; Jack, R.M.; Kho, R.; Lang, H.; Ma, C.-T.; Meininger, D.; Pellecchia, M.; Pierre, F.; Villar, H.; Yu, L. Systems-based design of bi-ligand inhibitors of oxidoreductases: Filling the chemical proteomic toolbox. Chem. Biol., 2004, 11, 185-94.
162. Kuroda, T.; Yamauchi, T.; Shinohara, T.; Oshima, K.; Kitajima, C.; Nagao, H.; Ishiyama, H.; Ohta, K.; Takano, M.; Sumida, T. Carbazole compound. WO 2007119600 A1 2007.
163. Safonov, I.G.; Heerding, D.A.; Keenan, R.M.; Price, A.T.; Erickson-Miller, C.L.; Hopson, C.B.; Levin, J.L.; Lord, K.A.; Tapley, P.M. New benzimidazoles as thrombopoietin receptor agonists. Bioorg. Med. Chem. Lett., 2006, 16, 1212-6.
164. 6 coenzyme analog derived from pyridoxal 5′-phosphate and rhodanine. Tetrahedron, 1996, 52, 14787-800.
165. 6 analogue modulates pathophysiological cell proliferation and damage. Bioorg. Med. Chem., 1999, 7, 359-67.
166. 6 conjugate analogues for antiviral chemotherapy. Biochem. Biophys. Res. Commun., 2003, 300, 793-9.
167. Szewczuk, L.M.; Saldanha, S.A.; Ganguly, S.; Bowers, E.M.; Javoroncov, M.; Karanam, B.; Culhane, J.C.; Holbert, M.A.; Klein, D.C.; Abagyan, R.; Cole, P.A. De novo discovery of serotonin N-acetyltransferase inhibitors. J. Med. Chem., 2007, 50, 5330-8.
168. Martinez, A.; Alonso, M.; Castro, A.; Dorronsoro, I.; Gelpí, J.L.; Luque, F.J.; Pérez, C.; Moreno, F.J. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: Exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J. Med. Chem., 2005, 48, 7103-12.
169. Kim, H.-J.; Choo, H.; Cho, Y.S.; No, K.T.; Pae, A.N. Novel GSK-3β inhibitors from sequential virtual screening. Bioorg. Med. Chem., 2008, 16, 636-43.
170. Howard, M.H.; Cenizal, T.; Gutteridge, S.; Hanna, W.S.; Tao, Y.; Totrov, M.; Wittenbach, V.A.; Zheng, Y. A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. J. Med. Chem., 2004, 47, 6669-72.
171. Ma, T.; Thiagarajah, J.R.; Yang, H.; Sonawane, N.D.; Folli, C.; Galietta L.J.V.; Verkman, A.S. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest., 2002, 110, 1651-.
172. Taddei, A.; Folli, C.; Zegarra-Moran, O.; Fanen, P.; Verkman, A.S.; Galietta, L.J.V. Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett., 2004, 558, 52-6.
173. Thiagarajah, J.R.; Broadbent, T.; Hsieh, E.; Verkman, A.S. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology, 2004, 126, 511-9.
174. Sonawane, N.D.; Muanprasat, C.; Nagatani Jr., R.; Song, Y.; Verkman, A.S. In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. J. Pharm. Sci., 2005, 94, 134-43.
175. Ma, T.; Vetrivel, L.; Yang, H.; Pedemonte, N.; Zegarra-Moran, O.; Galietta, L.J.V., Verkman, A.S. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J. Biol. Chem., 2002, 277, 37235-41.
176. Ebisawa, M.; Inoue, N.; Fukasawa, H.; Sotome, T.; Kagechika, H. Thiazolidinediones with thyroid hormone receptor agonistic activity. Chem. Pharm. Bull., 1999, 47, 1348-50.
177. Hashimoto, A.; Shi, Y.; Drake, K.; Koh, J.T. Design and synthesis of complementing ligands for mutant thyroid hormone receptor TR..(R320H): A tailor-made approach toward the treatment of resistance to thyroid hormone. Bioorg. Med. Chem., 2005, 13, 3627-39
178. Komatsu, T.; Hirano, T.; Songkram, C.; Kawachi, E.; Kagechika, H. Novel thyroid hormone receptor antagonists with an N-alkylated diphenylamine skeleton. Bioorg. Med. Chem., 2007, 15, 3115-26
179. 3 agonists. Bioorg. Med. Chem. Lett., 2001, 11, 757-60.
180. 3 agonists. Bioorg. Med. Chem. Lett., 2001, 11, 981-4.
181. St. Jean Jr., D.J.; Yuan, C.; Bercot, E.A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate, R.W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C. 2-(S)-Phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteriod dehydrogenase type 1. J. Med. Chem., 2007, 50, 429-32.
182. Yuan, C.; St. Jean Jr., D.J.; Liu, Q.; Cai, L.; Li, A.; Han, N.; Moniz, G.; Askew, B.; Hungate, R.W.; Johansson, L.; Tedenborg, L.; Pyring, D.; Williams, M.; Hale, C.; Chen, M.; Cupples, R.; Zhang, J.; Jordan, S.; Bartberger, M.D.; Sun, Y.; Emery, M.; Wang, M.; Fotsch, C. The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6056-61.
183. McGovern, S.L.; Shoichet, B.K. Kinase inhibitors: Not just for kinases anymore. J. Med. Chem., 2003, 43, 1478-83.
184. Babaoglu, K.; Simeonov, A.; Irwin, J.J.; Nelson, M.E.; Feng, B.; Thomas, C.J.; Cancian, L.; Costi, M.P.; Maltby, D.A.; Jadhav, A.; Inglese, J.; Austin, C.P.; Shoichet, B.K. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase. J. Med. Chem., 2008, 51, 2502-11.